The introduction of pneumococcal conjugate vaccines (PCVs) into pediatric national immunization programs (NIP) has significantly reduced invasive pneumococcal diseases and pneumococcal pneumonia caused by PCV serotypes in adults due to herd immunity. However, diseases caused by PCV13 serotypes persist, mainly serotype 3, known for its severity. With the reduction in PCV13 serotypes, diseases caused by non-PCV13 serotypes increased. Residual and emerging serotypes vary regionally
serotype 8 in Europe and South Africa, and serotype 4 in the US and Canada. PCV20 and PCV21 were recently developed, which can prevent residual and emerging pneumococcal diseases where herd immunity is well-established. In countries that have not introduced PCV into pediatric NIP, the pneumococcal disease burden due to PCV serotypes is still marked. Given that serotype distribution varies by region and evolves over time, this review aimed to discuss serotype distribution and disease severity in adults across countries to support future pneumococcal vaccine strategies.